MedHub-AI Secures National Reimbursement Approval in Japan for AI-Powered Coronary Assessment System
核心洞察
The Japanese Ministry of Health, Labour and Welfare approved national reimbursement for MedHub-AI (搜索)'s AutocathFFR (搜索) System, effective October 1, 2025, following earlier regulatory approval by PMDA.
AutocathFFR (搜索) represents the first fully automated, real-time AI-based fractional flow reserve solution that eliminates the need for pressure wires or hyperemic agents during coronary angiography.
The system applies advanced AI algorithms directly to routine angiographic images, producing physiology results instantly and reproducibly within procedures, addressing coronary artery disease assessment needs.
MedHub-AI (搜索) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved national reimbursement for the company's AutocathFFR (搜索)™ System, effective October 1, 2025. The decision follows regulatory approval by the Pharmaceuticals and Medical Devices Agency (PMDA) earlier this year and marks a significant milestone in expanding access to advanced coronary physiology assessment in Japan.
The approval provides physicians and hospitals across Japan with broad access to AutocathFFR (搜索), the first fully automated, real-time AI-based fractional flow reserve (FFR) solution performed intra-procedurally during coronary angiography. By removing the need for pressure wires or hyperemic agents, AutocathFFR integrates seamlessly into the cath lab workflow, enabling fast and precise assessment of coronary artery disease (CAD).
Addressing Critical Healthcare Needs
Coronary artery disease is the number one cause of morbidity and mortality worldwide, including in Japan where the burden of cardiovascular disease continues to rise. The introduction of AI-driven, non-invasive physiology represents an important advancement for both clinicians and patients by supporting evidence-based decision-making, reducing procedural complexity, and potentially lowering overall healthcare costs.
With reimbursement now established, AutocathFFR (搜索) is positioned to play a central role in improving access to advanced CAD assessment throughout Japan. This milestone further strengthens MedHub-AI (搜索)'s strategic collaboration with Terumo Corporation to accelerate adoption and integration of AutocathFFR across hundreds of hospitals nationwide.
Technical Differentiation and Clinical Advantages
Unlike 3D image reconstruction-based physiology technologies that require complex processing, manual steps, and time-consuming analysis, AutocathFFR (搜索) is fully automated and does not rely on 3D modeling of coronary anatomy. Instead, it applies advanced AI algorithms directly to routine angiographic images, producing physiology results instantly and reproducibly within the procedure.
This unique approach reduces operator dependency, shortens analysis time, and enhances consistency across patients and centers. These advantages make AutocathFFR (搜索) ideally suited for broad adoption in daily practice, ensuring that physiology assessment is available for every case, not just selected patients.
System Specifications and Clinical Validation
AutocathFFR (搜索) is characterized by several key features that distinguish it in the coronary assessment landscape:
- Non-invasive approach: Requires no pressure wires or pharmacologic hyperemia
- Real-time efficiency: Provides results in seconds without disrupting workflow
- Reproducible outcomes: Automated AI eliminates variability and ensures consistent results
- Clinical validation: Multi-center studies have demonstrated equivalence to invasive FFR methods
"Reimbursement approval in Japan represents a major achievement for MedHub-AI (搜索) and validates the clinical and economic value of AutocathFFR (搜索)," said Or Bruch-El, Chief Executive Officer of MedHub-AI. "This milestone underscores our commitment to advancing coronary physiology worldwide and to ensuring that patients and physicians have access to innovative, AI-driven solutions that transform clinical practice."
AutocathFFR (搜索) has received regulatory approvals in Japan and is part of MedHub-AI (搜索)'s broader global strategy to expand access to AI-driven solutions for cardiovascular care.